<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620539</url>
  </required_header>
  <id_info>
    <org_study_id>ICM2017-2312</org_study_id>
    <nct_id>NCT03620539</nct_id>
  </id_info>
  <brief_title>Sauna Bathing to Improve Vascular Health of Adults With Heart Disease</brief_title>
  <official_title>Effects of Sauna Bathing on Cerebrovascular Function in Middle-aged to Older Adults With Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical trial that will determine if sauna bathing improves blood vessel
      health in adults aged 50-70 years with heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mounting evidence suggests that heat therapy may improve cardiovascular health. Recent
      analyses of a large cohort of middle-aged to older Finnish men have established that frequent
      sauna bathing is associated with a reduced risk of cardiovascular mortality, of developing
      dementia and Alzheimer's disease, and of developing hypertension. Given the observational
      nature of these relationships, it remains unknown if the beneficial effects of sauna bathing
      can be directly attributed to heat exposure.

      The objective of this study is to test the primary hypothesis that 8 weeks of sauna bathing
      improves flow-mediated dilation, a measure of blood vessel health, in middle-aged to older
      adults (50-70 yrs) with stable coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Brachial artery flow-mediated dilation in response to 5 minutes of forearm occlusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-occlusion reactive hyperaemia (AUC)</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Vascular conductance area-under-the-curve during reactive hyperaemia induced by 5 minutes of forearm occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-occlusion reactive hyperaemia (Peak)</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Peak vascular conductance during reactive hyperaemia induced by 5 minutes of forearm occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local skin heating-induced vasodilation</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Plateau of the cutaneous vascular conductance response during local heating of the skin to 39°C</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Systolic blood pressure at rest</description>
  </other_outcome>
  <other_outcome>
    <measure>Central arterial stiffness</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Carotid-femoral pulse wave velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Change from baseline after 8 weeks</time_frame>
    <description>Resting levels of heart rate variability</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the control condition will be asked to maintain their normal daily habits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sauna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>Sauna bathing</description>
    <arm_group_label>Sauna</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A history of angiographic coronary disease: ≥70% arterial diameter narrowing of at
             least one major epicardial coronary artery and/or prior coronary revascularization
             and/or documented prior acute coronary syndrome and/or perfusion defect during
             exercise testing or pharmacological stimulation

          2. Stable medication doses (≥4 weeks) prior to enrolment

          3. Body mass index &lt;35 kg/m2

        Exclusion Criteria:

          1. Recent (&lt;3 months) coronary artery disease-related hospitalization or change in angina
             pattern

          2. Unstable angina

          3. Ejection fraction &lt;40% and/or clinical evidence of heart failure

          4. Significant valvular heart disease

          5. Uncontrolled hypertension (&gt;180/110 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Gagnon</last_name>
    <phone>1-514-374-1480</phone>
    <phone_ext>4205</phone_ext>
    <email>daniel.gagnon.3@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hugo Gravel</last_name>
    <phone>1-514-374-1480</phone>
    <phone_ext>4342</phone_ext>
    <email>hugo.gravel@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Prevention and Rehabilitation Centre of the Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T1N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gagnon, PhD</last_name>
      <phone>514-374-1480</phone>
      <phone_ext>4205</phone_ext>
      <email>daniel.gagnon.3@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flow-mediated dilation</keyword>
  <keyword>sauna</keyword>
  <keyword>vascular</keyword>
  <keyword>heat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

